Outlook Therapeutics (OTLK) Short Interest Ratio & Short Volume $1.77 -0.02 (-1.12%) As of 02:50 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Outlook Therapeutics Short Interest DataOutlook Therapeutics (OTLK) has a short interest of 3.22 million shares, representing 15.17% of the float (the number of shares available for trading by the public). This marks a 2.22% increase in short interest from the previous month. The short interest ratio (days to cover) is 6.1, indicating that it would take 6.1 days of the average trading volume of 621,431 shares to cover all short positions.Current Short Interest3,220,000 sharesPrevious Short Interest3,150,000 sharesChange Vs. Previous Month+2.22%Dollar Volume Sold Short$5.96 millionShort Interest Ratio6.1 Days to CoverLast Record DateMay 31, 2025Outstanding Shares33,568,000 sharesFloat Size21,220,000 sharesShort Percent of Float15.17%Today's Trading Volume515,518 sharesAverage Trading Volume621,431 sharesToday's Volume Vs. Average83% Short Selling Outlook Therapeutics? Sign up to receive the latest short interest report for Outlook Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartOTLK Short Interest Over TimeOTLK Days to Cover Over TimeOTLK Percentage of Float Shorted Over Time Outlook Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/31/20253,220,000 shares $5.96 million +2.2%15.2%6.1 $1.85 5/15/20253,150,000 shares $5.28 million -12.0%11.7%6.8 $1.68 4/30/20253,580,000 shares $5.62 million -10.5%17.5%8.8 $1.57 4/15/20254,000,000 shares $5.56 million +6.7%19.5%8.3 $1.39 3/31/20253,750,000 shares $4.58 million -4.6%18.3%6.2 $1.22 3/15/20253,930,000 shares $6.17 million +12.3%19.2%5.1 $1.57 2/28/20253,500,000 shares $5.25 million -0.9%14.8%3.9 $1.50 2/15/20253,530,000 shares $6.60 million +13.5%15.0%1.7 $1.87 1/31/20253,110,000 shares $6.41 million -1.6%14.7%1.5 $2.06 1/15/20253,160,000 shares $7.27 million +9.3%19.2%1.6 $2.30 Get the Latest News and Ratings for OTLK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Outlook Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/20242,890,000 shares $5.46 million -17.7%18.0%1.6 $1.89 12/15/20243,510,000 shares $5.19 million -15.0%23.1%2.2 $1.48 11/30/20244,130,000 shares $8.47 million +21.5%27.1%2.6 $2.05 11/15/20243,400,000 shares $18.39 million +5.3%22.3%12.3 $5.41 10/31/20243,230,000 shares $18.60 million +8.0%21.2%12.7 $5.76 10/15/20242,990,000 shares $15.31 million +1.4%19.6%12.2 $5.12 9/30/20242,950,000 shares $15.75 million +19.4%19.4%13.2 $5.34 9/15/20242,470,000 shares $15.98 million +1.7%16.2%10.8 $6.47 8/31/20242,430,000 shares $17.86 million No Change15.9%12 $7.35 8/15/20242,430,000 shares $18.66 million +4.7%16.0%11.5 $7.68 7/31/20242,320,000 shares $17.98 million +8.4%15.5%9.8 $7.75 7/15/20242,140,000 shares $18.08 million +9.7%14.3%9 $8.45 6/30/20241,950,000 shares $14.39 million +18.2%13.0%7.8 $7.38 6/15/20241,650,000 shares $12.66 million -0.6%9.7%4.8 $7.67 5/31/20241,660,000 shares $11.74 million +24.8%10.0%2.4 $7.07 5/15/20241,330,000 shares $9.88 million +5.6%8.0%2 $7.43 4/30/20241,260,000 shares $11.24 million +11.5%7.7%2 $8.92 4/15/20241,130,000 shares $9.74 million -15.0%7.4%1.8 $8.62 3/31/20241,330,000 shares $15.88 million +69.4%6.2%2.2 $11.94 3/15/2024785,300 shares $6.47 million -93.3%10.6%1.6 $8.24 2/29/202411,640,000 shares $5.08 million -11.8%7.9%6 $0.44 2/15/202413,200,000 shares $6.40 million -2.7%9.0%6.5 $0.48 1/31/202413,570,000 shares $5.24 million +11.9%9.2%5.9 $0.39 1/15/202412,130,000 shares $4.47 million +7.3%9.2%1.9 $0.37 12/31/202311,310,000 shares $4.46 million +3.3%8.6%1.6 $0.39 12/15/202310,950,000 shares $4.20 million -32.1%8.3%1.5 $0.38 11/30/202316,130,000 shares $7.74 million -21.5%12.2%2.1 $0.48 11/15/202320,540,000 shares $9.16 million -35.9%16.0%1.8 $0.45 10/31/202332,030,000 shares $19.22 million +9.4%25.0%2.8 $0.60 10/15/202329,270,000 shares $9.51 million +9.5%22.9%3.2 $0.33[No Brainer Gold Play]: “Show me a better investment.” (Ad)A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Click here to get Garrett’s Top Four picks now. 9/30/202326,720,000 shares $5.91 million +3.4%20.9%4.5 $0.22 9/15/202325,850,000 shares $5.56 million -3.0%20.2%4.6 $0.22 8/31/202326,660,000 shares $6.08 million +52.3%21.1%5.2 $0.23 8/15/202317,510,000 shares $27.14 million +4.9%13.9%12.2 $1.55 7/31/202316,700,000 shares $28.89 million +1.8%13.4%13.1 $1.73 7/15/202316,410,000 shares $27.08 million -2.2%13.2%13.2 $1.65 6/30/202316,770,000 shares $29.18 million -1.9%13.5%15.2 $1.74 6/15/202317,100,000 shares $30.44 million +3.9%13.7%16.6 $1.78 5/31/202316,460,000 shares $24.69 million +0.6%13.2%19.1 $1.50 5/15/202316,370,000 shares $19.64 million -3.1%13.1%24.5 $1.20 4/30/202316,890,000 shares $17.73 million +0.6%13.6%28.6 $1.05 4/15/202316,790,000 shares $18.13 million +2.2%13.6%29.7 $1.08 3/31/202316,430,000 shares $17.91 million +6.1%13.3%27.6 $1.09 3/15/202315,490,000 shares $15.64 million +2.9%12.5%24.9 $1.01 2/28/202315,050,000 shares $16.40 million -1.4%12.2%27.1 $1.09 2/15/202315,270,000 shares $17.71 million -2.9%12.4%29 $1.16 1/31/202315,730,000 shares $18.09 million +3.8%11.7%32 $1.15 1/15/202315,150,000 shares $20.45 million -5.4%12.7%30.2 $1.35 12/30/202216,020,000 shares $17.30 million +0.4%33.0%36.9 $1.08 12/15/202215,960,000 shares $14.37 million -1.1%12.1%34.6 $0.90 11/30/202216,130,000 shares $16.78 million -1.7%12.2%35.1 $1.04 11/15/202216,400,000 shares $17.38 million +3.0%12.4%34.7 $1.06 10/31/202215,930,000 shares $18.48 million +3.6%12.0%33.8 $1.16 10/15/202215,380,000 shares $18.46 million +6.7%11.6%33.4 $1.20 9/30/202214,420,000 shares $17.59 million +5.6%10.9%30.8 $1.22 9/15/202213,660,000 shares $15.71 million +9.2%10.3%29.1 $1.15 8/31/202212,510,000 shares $14.01 million +2.6%9.4%26.3 $1.12 8/15/202212,190,000 shares $15.36 million -0.7%9.2%13.9 $1.26 7/31/202212,280,000 shares $13.88 million +4.0%9.3%12.9 $1.13 7/15/202211,810,000 shares $13.82 million +5.7%8.9%12.2 $1.17 6/30/202211,170,000 shares $11.39 million +4.7%8.4%11 $1.02 6/15/202210,670,000 shares $10.59 million -8.3%6.5%9 $0.99 5/31/202211,640,000 shares $13.39 million +4.2%7.1%8.3 $1.15 5/15/202211,170,000 shares $17.87 million +4.6%6.8%9.3 $1.60 4/30/202210,680,000 shares $16.55 million +1.0%6.5%8.7 $1.55 4/15/202210,580,000 shares $19.26 million +9.3%9.9%7.6 $1.82 3/31/20229,680,000 shares $17.23 million +48.9%N/A6.5 $1.78 3/15/20226,500,000 shares $11.51 million +8.5%N/A4.6 $1.77 2/28/20225,990,000 shares $9.76 million +9.3%4.9%4.5 $1.63 2/15/20225,480,000 shares $7.67 million +3.4%4.5%3.4 $1.40 1/31/20225,300,000 shares $7.53 million +25.0%4.4%3.2 $1.42 1/15/20224,240,000 shares $5.64 million -1.9%3.5%2.8 $1.33 12/31/20214,320,000 shares $5.88 million +0.9%3.5%3.2 $1.36 12/15/20214,280,000 shares $6.21 million +16.3%3.5%3.2 $1.45 11/30/20213,680,000 shares $5.56 million -41.6%4.0%2.8 $1.51 11/15/20216,300,000 shares $12.29 million -1.4%7.1%5.7 $1.95 10/29/20216,390,000 shares $13.23 million +8.7%7.2%7.1 $2.07 10/15/20215,880,000 shares $12.41 million -3.5%6.7%2 $2.11 9/30/20216,090,000 shares $13.22 million +8.2%6.9%2.1 $2.17 9/15/20215,630,000 shares $13.62 million -0.5%6.4%1.8 $2.42[No Brainer Gold Play]: “Show me a better investment.” (Ad)A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.Click here to get Garrett’s Top Four picks now. 8/31/20215,660,000 shares $15.62 million +1.4%6.4%1.8 $2.76 8/13/20215,580,000 shares $13.39 million +71.7%6.3%1.8 $2.40 7/30/20213,250,000 shares $7.35 million +3.2%3.7%1.1 $2.26 7/15/20213,150,000 shares $7.15 million -25.2%3.6%3.4 $2.27 6/30/20214,210,000 shares $10.48 million +214.2%4.8%4.2 $2.49 6/15/20211,340,000 shares $3.46 million +6.4%1.5%1.5 $2.58 5/28/20211,260,000 shares $3.38 million +15.6%1.4%1.3 $2.68 5/14/20211,090,000 shares $2.11 million +41.8%N/A1 $1.94 4/30/2021768,600 shares $1.79 million +155.3%N/A0.3 $2.33 4/15/2021301,100 shares $563.06 thousand -34.1%N/A0.1 $1.87 3/31/2021457,100 shares $996.48 thousand +30.8%N/A0.1 $2.18 3/15/2021349,500 shares $782.88 thousand +20.8%N/A0.1 $2.24 2/26/2021289,400 shares $616.42 thousand -67.3%N/A0.1 $2.13 2/12/2021884,100 shares $2.29 million -55.1%N/A0.2 $2.59 1/29/20211,970,000 shares $2.40 million +25.5%N/A0.5 $1.22 1/15/20211,570,000 shares $1.93 million -19.9%N/A1.8 $1.23 12/31/20201,960,000 shares $2.61 million -2.5%N/A2.1 $1.33 12/15/20202,010,000 shares $2.65 million -3.4%N/A2.3 $1.32 11/30/20202,080,000 shares $2.56 million -25.2%N/A2.3 $1.23 11/15/20202,780,000 shares $2.89 million -13.9%N/A1.7 $1.04 10/30/20203,230,000 shares $2.60 million +4.5%N/A1.7 $0.81 10/15/20203,090,000 shares $2.70 million +8.8%N/A1.4 $0.87 9/30/20202,840,000 shares $2.04 million +16.9%N/A1.1 $0.72 9/15/20202,430,000 shares $1.56 million -9.3%N/A0.8 $0.64 8/31/20202,680,000 shares $1.77 million +0.4%N/A0.7 $0.66 8/14/20202,670,000 shares $3.74 million +29.6%N/A0.8 $1.40 7/31/20202,060,000 shares $2.80 million -11.6%N/A0.7 $1.36 7/15/20202,330,000 shares $3.22 million +8.9%N/A0.8 $1.38 6/30/20202,140,000 shares $2.76 million -23.3%8.2%0.9 $1.29 6/15/20202,790,000 shares $3.12 million +29.8%14.3%1.6 $1.12 OTLK Short Interest - Frequently Asked Questions What is Outlook Therapeutics' current short interest? Short interest is the volume of Outlook Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 31st, traders have sold 3,220,000 shares of OTLK short. 15.17% of Outlook Therapeutics' shares are currently sold short. Learn More on Outlook Therapeutics' current short interest. What is a good short interest ratio for Outlook Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. OTLK shares currently have a short interest ratio of 6.0. Learn More on Outlook Therapeutics's short interest ratio. What is a good short interest percentage for Outlook Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 15.17% of Outlook Therapeutics' floating shares are currently sold short. Is Outlook Therapeutics' short interest increasing or decreasing? Outlook Therapeutics saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 3,220,000 shares, an increase of 2.2% from the previous total of 3,150,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Outlook Therapeutics' float size? Outlook Therapeutics currently has issued a total of 33,568,000 shares. Some of Outlook Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Outlook Therapeutics currently has a public float of 21,220,000 shares. How does Outlook Therapeutics' short interest compare to its competitors? 15.17% of Outlook Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Outlook Therapeutics: Tevogen Bio Holdings Inc. (6.70%), Annexon, Inc. (10.71%), Foghorn Therapeutics Inc. (3.94%), Acelyrin, Inc. (4.87%), Design Therapeutics, Inc. (11.86%), UroGen Pharma Ltd. (17.61%), Cardiff Oncology, Inc. (37.39%), Canopy Growth Co. (9.91%), ProKidney Corp. (18.12%), Genfit S.A. (0.08%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($64.96 billion), Invesco QQQ ($27.88 billion), iShares Russell 2000 ETF ($19.94 billion), iShares 20+ Year Treasury Bond ETF ($9.69 billion), Strategy Incorporated ($8.58 billion), SPDR S&P Biotech ETF ($5.72 billion), Invesco S&P 500 Equal Weight ETF ($5.45 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.70 billion), Charter Communications, Inc. ($4.54 billion), and Industrial Select Sector SPDR Fund ($4.49 billion). View all of the most shorted stocks. What does it mean to sell short Outlook Therapeutics stock? Short selling OTLK is an investing strategy that aims to generate trading profit from Outlook Therapeutics as its price is falling. OTLK shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Outlook Therapeutics? A short squeeze for Outlook Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of OTLK, which in turn drives the price of the stock up even further. How often is Outlook Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OTLK, twice per month. The most recent reporting period available is May, 31 2025. More Short Interest Resources from MarketBeat Related Companies Tevogen Bio Short Interest Data Annexon Short Interest Data Foghorn Therapeutics Short Interest Data Acelyrin Short Interest Data Design Therapeutics Short Interest Data UroGen Pharma Short Interest Data Cardiff Oncology Short Interest Data Canopy Growth Short Interest Data ProKidney Short Interest Data Genfit Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:OTLK) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Outlook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
